- Home
- EKSO vs BCAB Comparison
EKSO vs BCAB Comparison
Compare EKSO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EKSO | BCAB |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 20.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EKSO | BCAB |
|---|---|---|
| Price | $9.90 | $0.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.50 | $1.00 |
| AVG Volume (30 Days) | 203.4K | ★ 3.3M |
| Earning Date | 03-02-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $54.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.73 | $0.14 |
| 52 Week High | $12.70 | $1.43 |
Technical Indicators
Market Signals| Indicator | EKSO | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 29.22 |
| Support Level | $8.39 | $0.18 |
| Resistance Level | $10.76 | $0.21 |
| Average True Range (ATR) | 0.94 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 75.35 | 15.31 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.